On the effect of amantadine on monoamines and their metabolites in the brain and cerebrospinal fluid

@article{Rinne1972OnTE,
  title={On the effect of amantadine on monoamines and their metabolites in the brain and cerebrospinal fluid},
  author={Urpo K. Rinne and V J Sonninen and Markku T. Hyypp{\"a}},
  journal={Experientia},
  year={1972},
  volume={28},
  pages={57-59}
}
Nachweis des stark herabgesetzten Säuregehalts der Homovanillinsäure und der 5-Hydroxy-indolessigsäure im Liquor cerebrospinalis von Parkinsonkranken im Vergleich mit normalen Versuchspersonen. Die Amantadin-Therapie hingegen ergab keine bedeutenden veränderungen und der Gehalt von Dopamin, Noradrenalin und Homovanillinsäure im Gehirn der behandelten Parkinsonpatienten entsprach auch den Werten der übrigen Parkinsonkranken. Ausserdem hatte Amantadin keinen Einfluss auf den endogenen Gehalt… 
View on Springer
ncbi.nlm.nih.gov
3 Citations
Background Citations
1

3 Citations

On the effect of amantadine on ATP content and ATPase activity in brain and blood of rats

Nachweis, dass Amantadin-HCl die Aktivität der K−Na-ATPase im Hirnstamm von Ratten erhöht, wird die Veränderung der Membranpermeabilität verantwortlich gemacht.

Amantadine actions on acetylcholine and GABA in striatum and substantia nigra of rat in relation to behavioral changes

The locomotor hyperactivity and the circling movements after amantadine hydrochloride may result from the inhibition of recurrent nigro striatal (dopaminergic) fibers influenced by the increased GABA activity in the substantia nigra, thereby causing disinhibition of the pallidar structures for locomotor activity.

Amantadine: reappraisal of the timeless diamond—target updates and novel therapeutic potentials

Considering amantadine’s affinities in vitro and the expected concentration at targets at therapeutic doses in humans, the following primary targets seem to be most plausible: aromatic amino acids decarboxylase, glial-cell derived neurotrophic factor, sigma-1 receptors, phosphodiesterases, and nicotinic receptors.

References

SHOWING 1-10 OF 20 REFERENCES

Amantadine-Dopamine Interaction: Possible Mode of Action in Parkinsonism

Intravenous doses of amantadine hydrochloride, an antiviral drug, as small as 0.08 milligram per kilogram may release dopamine and other catecholamines from neuronal storage sites in dogs primed with…

In‐Vivo Decarboxylation of α‐Methyl DOPA and α‐Methyl Metatyrosine

The drop in noradrenaline and dopamine levels in brain caused by the α-methyl amino acids appears to be largely due to displacement by these decarboxylation products, which may possibly also take over the functions of the physiological amines.

Drug-induced changes in the concentration of 5-OR indolyl compounds in cerebrospinal fluid and caudate nucleus.

The effects of reserpine and imipramine on the concentration of indolyl compounds bearing an OR group in position 5 in the cerebrospinal fluid and the caudate nucleus of the dog have been studied.

Rapid method for the determination of 5‐hydroxytryptamine and 5‐hydroxyindoleacetic acid in small regions of rat brain

A rapid and sensitive method for measuring 5‐hydroxytryptamine and 5‐hydroxyindoleacetic acid, using o‐phthalaldehyde and L‐cysteine, is presented, enabling both compounds to be measured in small…

Increased synthesis and release of dopamine in the striatum of the rat after amantadine treatment.

Amantadine in parkinsonism.

Amantadine in the treatment of Parkinson's disease.

Sixty-six percent of a group of 163 patients with Parkinson's disease exhibited subjective or objective improvement of their akinesia, rigidity, and tremor while receiving amantadine hydrochloride.…

AMANTADINE HYDROCHLORIDE IN THE TREATMENT OF PARKINSON'S DISEASE

A double‐blind control trial of amantadine hydrochloride in a dosage of 200 mg per day, and placebo, confirms the results of previous studies, which showed that the drug is a well‐tolerated drug and has a beneficial effect of varying degree on the disease.

Controlled trial of amantadine hydrochloride in Parkinson's disease.

Parkinsonism: Onset, progression, and mortality

Controversy over the effectiveness of therapeutic measures for parkinsonism is due partially to this wide variability and to the paucity of clinical information about the natural history of the syndrome.